Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma

S. Schneider(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), É. Alezra(Centre Hospitalier Universitaire de Bordeaux), Mokrane Yacoub(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Océane Ducharme(Centre Hospitalier Universitaire de Bordeaux)
Melanoma Research
August 23, 2021
10.1097/cmr.0000000000000765
Cited by 17

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k